Avantis now identifies as Veranta. Its current material describes USDC margin on Base and distinct fee models for RWA trading and Upside Perps. Neither a rebrand nor a zero-commission headline establishes total cost, safety or eligibility.
Reviewed 2026-10-14Version 1.0.0No live execution tests
What Matters
The name changed. Recheck the conditions.
Provider-documentation review, not a live trading test, security audit or personalised eligibility assessment. Detailed fee and permission pages could not be retrieved during this review.
Old Avantis instructions may describe a different product configuration. This brief records what current accessible provider sources establish and leaves unsupported details unknown.
DN Evidence Block
Claims, sources and practical consequences.
Provider-reported
Is this still Avantis?
The developer organisation identifies Veranta as formerly Avantis. The old official website and documentation redirected to Veranta during this review.
Why it matters: Use the current name and documentation; do not assume older instructions still describe the product.
The overview describes zero maker/taker fees for RWAs while in growth mode, alongside spreads and carry. Upside Perps, previously ZFP, take fees from profits.
Why it matters: Identify the product mode and inspect its current cost breakdown. This brief does not verify a complete numerical fee schedule.
The overview advertises gasless one-click execution. DN did not inspect a live approval flow or verify the scope, duration and revocation of any delegated permissions.
Why it matters: Inspect signing requests and revocation controls independently. Gas sponsorship does not establish a safe permission boundary.
Complete permission scope and revocation behaviour
Live execution, stop-loss and withdrawal performance
Individual legal access and suitability
Detail pages unavailable during this review
Collateral & Position Sizing detail page
Fee Schedule by Asset Class detail page
Upside Perps profit-sharing detail page
Gasless / One-Click Trading detail page
The overview, provider product explanation and terms were accessible. Missing details are not filled with historical rates or third-party assumptions.
No numerical all-in cost is calculated. A valid comparison needs contemporaneous quotes for matching assets, product modes, notional sizes, directions and holding periods, with entry, holding and exit costs included.
Your research record
Keep the evidence. Keep its limits.
The receipt preserves the provider sources and research gaps at version 1.0.0.
It is not a recommendation, approval, live quote or alert subscription. No account, balance, wallet or country is requested.
Initial Veranta brief with Avantis alias. Verified the identity using provider sources; recorded detail-page access gaps. This is the DN review date, not the rebrand announcement date.
Review triggers: Accessible detail pages or changed provider documentation; A substantiated correction; The 14-day review deadline. No automated provider surveillance runs for this brief.
How to use this research
Provider-reported describes the source of a statement, not an independent endorsement. Unknown and not measured identify evidence gaps. A documentation review does not confer an operational-status classification or establish user eligibility.
DN has an existing Avantis referral entry. Its applicability after the rebrand has not been verified in this brief. No new referral destination or active partner CTA is supplied. Compensation has no role in the evidence labels.
Educational research only, not investment, legal or tax advice. Leveraged derivatives can cause substantial losses.